India'a largest pharmaceutical company Ranbaxy Laboratories Ltd has finally got nod from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) and Quinapril Hydrochloride & Hydrochlotothiazide (Quinapril + HCTZ) Tablets, an ACE inhibitor which is used to treat high blood pressure.
The company received approval for tablets in strength of 10mg/12.5mg, 20 mg/12.5mg and 20mg/225mg respectively.
An official release stated that, the office of Generic Drugs, USFDA, had determined the Ranbaxy formulations to be bioequivalent and as having the same therapeutic effect as that of the reference listed drug, Accuretic Tablets of Pfizer Pharmaceuticals Ltd.
It should be noted that this is the second ANDa approval granted by the USFDA, to Ranbaxy, in the last two months.
The application for the drug was submitted by Ranbaxy, from OHM Laboratories manufacturing facility, at New Jersey, USA.
Popular content
Today's:
All time:
Last viewed:
- Mortgage Rates Might Rise in Spring of 2010 - Fed
- Google apologizes to Chinese authors for including their books in its Book Search project
- Toshiba announces TG01, the potential rival of iPhone 3G & BlackBerry Storm
- $1.88 billion raised by Verisk IPO
- Facebook’s recent ‘privacy revamp’ lambasted by users
- Chrysler-Fiat deal clears one hurdle, faces another
- Dell to manufacture ‘Mini 3i’ mobile handsets for China Mobile online store
- US Justice Department: Ruling against Jammie Thomas-Rasset “not excessive”
- Quarterly Profit Increase for Comcast
- Gazprom: Russia, Ukraine "nowhere near" deal ahead of gas cutoff



























